Get the Daily Brief
Latest Biotech News
GSK buys Empirico siRNA for COPD — $85M upfront, broad rights
GSK agreed to an exclusive license with Empirico for EMP‑012, a small interfering RNA candidate in Phase I for chronic obstructive pulmonary disease (COPD), paying $85 million up front with...
Zag Bio launches with $80M — thymus‑targeted tolerance platform
Zag Bio emerged from stealth with $80 million in committed funding to advance a platform that aims to induce immune tolerance by targeting the thymus. The startup is developing bifunctional...
Electra raises $183M Series C — pushes ELA026 pivotal sHLH trial
Electra Therapeutics closed an oversubscribed $183 million Series C financing to fund a global pivotal trial of ELA026, a monoclonal antibody addressing severe secondary hemophagocytic...
Novartis to buy Avidity: $12B bet on RNA neuromuscular drugs
Novartis agreed to acquire Avidity Biosciences in a cash transaction valued at about $12 billion, securing Avidity’s Antibody Oligonucleotide Conjugate (AOC) platform and three late-stage...
Intellia pauses CRISPR trials: liver toxicity triggers safety review
Intellia Therapeutics halted enrollment and dosing in two late-stage CRISPR trials after a patient receiving its in vivo transthyretin (ATTR) editing candidate was hospitalized with severe liver...
Lilly and Nvidia partner: building pharma’s most powerful AI supercomputer
Eli Lilly and Nvidia announced a strategic partnership to build what they describe as the most powerful supercomputer owned by a pharmaceutical company, aimed at training larger AI models for drug...
Lilly buys Adverum – one-time gene therapy for wet AMD
Eli Lilly agreed to acquire Adverum Biotechnologies to secure ixoberogene soroparvovec (ixo‑vec), a one-time AAV-based gene therapy in Phase III for wet age-related macular degeneration (wAMD)....
GSK licenses Empirico siRNA: $85M upfront for COPD candidate
GSK struck a licensing deal with Empirico to secure global rights to EMP‑012, a small-interfering RNA candidate in Phase 1 for chronic obstructive pulmonary disease (COPD). GSK will pay $85...
Electra raises $183M — funds pivotal sHLH trial and pipeline expansion
Electra Therapeutics closed an oversubscribed $183 million Series C to fund a global pivotal trial of ELA026, its monoclonal antibody targeting SIRP receptors, in secondary hemophagocytic...
FDA permits at‑home dosing for Delix: trial tests non‑hallucinogenic neuroplastogen
The FDA cleared at-home administration for Delix Therapeutics’ non‑hallucinogenic neuroplastogen in an upcoming Phase II depression study, allowing patients to self‑dose outside clinic settings....
Health Canada clears lecanemab: conditional approval for early Alzheimer’s
Health Canada issued a conditional Notice of Compliance for Eisai and Biogen’s lecanemab (LEQEMBI) to treat adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who...
Guardant inks Zephyr AI pact: multimodal genomics meets machine learning
Guardant Health entered a strategic partnership with Zephyr AI to combine Guardant’s multimodal molecular data from its genomic testing platforms with Zephyr’s AI and machine‑learning analytics to...
Zag Bio emerges with $80M: thymus-targeted Treg approach for autoimmunity
Zag Bio launched from stealth with roughly $80 million in disclosed funding to develop bifunctional antibodies that deliver tolerizing antigens to the thymus and induce regulatory T cell (Treg)...
Intellia pauses CRISPR trials—liver toxicity hospitalizes patient
Intellia Therapeutics paused enrollment and dosing in two late‑stage trials after a volunteer receiving its CRISPR candidate for transthyretin amyloidosis was hospitalized with severe liver...
Novartis buys Avidity: $12 billion deal expands RNA neuromuscular push
Novartis announced it will acquire Avidity Biosciences for roughly $12 billion to add three late‑stage antibody‑oligonucleotide conjugate (AOC) programs and Avidity’s muscle delivery platform to...
Lilly, Nvidia to build pharma supercomputer—AI-driven drug design scale-up
Eli Lilly partnered with Nvidia to construct what the companies say will be the most powerful supercomputer owned and operated by a pharmaceutical firm, aimed at training large AI models for drug...
GSK licenses Empirico siRNA—$85M upfront to broaden COPD pipeline
GSK paid $85 million up front for global rights to Empirico’s Phase‑1 siRNA candidate (EMP‑012) targeting inflammatory drivers of COPD and other respiratory diseases. The agreement gives GSK...
Electra raises $183M—pivotal trial starts for rare hyperinflammation drug
Electra Therapeutics closed an oversubscribed $183 million Series C to fund a global pivotal trial of ELA026, its monoclonal antibody candidate for secondary hemophagocytic lymphohistiocytosis...
Zag Bio launches: $80M to develop thymus‑targeted tolerizing therapies
Zag Bio emerged from stealth with $80 million in disclosed funding to advance bifunctional antibodies that traffic tolerizing antigens to the thymus and promote regulatory T cell (Treg)...
FDA allows at‑home dosing: Delix to test non‑hallucinogenic neuroplastogen
The FDA cleared at‑home administration for Delix Therapeutics’ next Phase‑2 study of a non‑hallucinogenic 'neuroplastogen' being developed for depression. Delix reported promising early clinical...